Michael H. Kramer, MD, PhD

Washington University in St. Louis (WU)

Dr. Kramer is a physician-scientist studying blood cancers, particularly acute myeloid leukemia (AML). He has studied the proteomics of AML, identifying examples of posttranscriptionally regulated proteins in patients with recurrent AML driver mutations, and cell surface proteins that may be targets for immunologic therapies. Dr. Kramer is interested in how recurrent mutations in NPM1 alter the post-transcriptional regulation of key signaling proteins in the cell, and how these events allow hematopoietic stem and progenitor cells to tolerate abnormal signaling events that drive and maintain leukemia. He is utilizing protein-protein interaction screening to identify interactions with oncogenic driver proteins that can be targeted therapeutically, and is utilizing machine learning to predict and design molecules that interact with oncogenic driver proteins. Clinically, Dr. Kramer sees patients on the inpatient Hematologic Malignancies service, and he is involved with running a clinical trial of allogeneic CAR T-cells for patients with leukemia and lymphoma.